Critical Comparison: Sight Sciences (SGHT) & The Competition

Sight Sciences (NASDAQ:SGHT) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Sight Sciences to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sight Sciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1	2	5	0	2.50
Sight Sciences Competitors	4291	10579	18360	831	2.46

Sight Sciences presently has a consensus price target of $9.62, suggesting a potential downside of 11.86%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.39%. Given Sight Sciences’ rivals higher possible upside, analysts clearly believe Sight Sciences has less favorable growth aspects than its rivals.

Risk & Volatility

Sight Sciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Sight Sciences’ rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Profitability

This table compares Sight Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-32.13%	-43.91%	-22.20%
Sight Sciences Competitors	-304.20%	-315.07%	-22.11%

Valuation & Earnings

This table compares Sight Sciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sight Sciences	$88.39 million	-$38.43 million	-21.00
Sight Sciences Competitors	$1.89 billion	$135.83 million	5.77

Sight Sciences’ rivals have higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sight Sciences rivals beat Sight Sciences on 7 of the 13 factors compared.

Sight Sciences Company Profile

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.